Form 4: Oramed Pharmaceuticals CFO Sells Shares
Statement of Changes in Beneficial Ownership
Oramed Pharmaceuticals CFO Avraham Gabay sold 73,360 shares of common stock on July 1, 2026, pursuant to a Rule 10b5-1 trading plan.
Summary
- Avraham Gabay, Chief Financial Officer of Oramed Pharmaceuticals Inc. (ORMP), reported a sale of 73,360 shares of common stock on July 1, 2026.
- The sale was executed under a Rule 10b5-1 trading plan adopted on March 30, 2026.
- The shares were sold at a weighted average price of $4.5085, with individual transactions ranging from $4.255 to $4.750.
- Following these transactions, Gabay beneficially owns 671,785 shares of common stock.
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the insider sale, though the pre-planned nature of the transaction under Rule 10b5-1 mitigates significant concern.
Negatives
- The CFO sold a significant number of shares, which could be perceived negatively by the market.
Future Outlook
No forward-looking statements or guidance were provided in this filing.
Industry Context
StockSavvy.ai notes that insider selling, particularly by a CFO, can sometimes signal a lack of confidence in future stock performance, although sales under a Rule 10b5-1 plan are pre-arranged and may not reflect current sentiment.
Stakeholder Impact
- Shareholders may view the CFO's sale of shares with caution, potentially impacting short-term stock sentiment.
- The sale, being part of a pre-arranged plan, is intended to avoid implications of insider trading and maintain compliance.
Key Dates
| Date | Description |
|---|---|
| 03/30/2026 | Date Rule 10b5-1 trading plan was adopted by Reporting Person. |
| 07/01/2026 | Earliest transaction date and date of common stock sale. |
| 07/02/2026 | Date of signature on the filing. |
Recommendation
holdThe filing reports an insider sale by the CFO under a pre-arranged Rule 10b5-1 plan. While insider selling can be a negative signal, the structured nature of this sale suggests it may not reflect current negative views on the company's prospects. Therefore, a 'hold' recommendation is appropriate pending further company news or performance indicators.
Keywords
Oramed Pharmaceuticals, ORMP, Form 4, Insider Trading, Share Sale, Rule 10b5-1, CFO, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.